Page 96 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Cripto-1 in cancer diagnosis and therapy

about potential sampling biases. For example, while groundwork for identifying radiosensitive prostate cancer
elevated Cripto-1 expression in colorectal cancer has subtypes, though it awaits clinical validation.
been associated with poor prognosis, this relationship Across a range of cancers, including breast, liver,
requires validation in larger patient cohorts to ensure lung, prostate, and melanoma, numerous studies report
reproducibility and statistical robustness. In breast cancer, a positive association between Cripto-1 expression and
Cripto-1 expression increases progressively from normal higher tumor grade or metastatic potential. Elevated
epithelium to carcinoma in situ and invasive carcinoma, Cripto-1 levels often correspond with increased metastatic
suggesting involvement in both tumor initiation and capacity and poorer prognosis. Nevertheless, conflicting
progression. Similarly, in non-small cell lung cancer, findings exist, with some smaller studies failing to replicate
elevated serum Cripto-1 levels have been correlated these associations, likely due to heterogeneity in patient
with tumor size, differentiation status, and overall tumor populations, tumor subtypes, and detection methodologies.
burden, with higher expression linked to predicting These discrepancies highlight the need for a multi-marker
poorer clinical outcomes. Analogous findings have approach to enhance diagnostic and prognostic precision,
59
been reported in HCC, where Cripto-1 is significantly as reliance on a single biomarker – such as Cripto-1 alone
overexpressed in tumor tissues compared to adjacent – is insufficient for robust disease stratification.
non-tumorous liver tissues. High Cripto-1 levels in HCC
correlate with aggressive features such as large tumor size, 4. Targeting Cripto-1 in tumor therapy
advanced clinical stage, vascular invasion (e.g., portal vein
tumor thrombus), and are associated with shorter disease- Advancements in tumor biology have established that
free survival, time to recurrence, and OS, indicating its carcinogenesis is driven by dysregulated cellular signaling
potential as an independent prognostic factor. However, pathways that promote uncontrolled cell proliferation,
60
survival, and metastasis. This understanding has shifted
most of these findings are derived from observational the focus of anticancer drug development from traditional
studies, and mechanistic validation is necessary to
establish causation. cytotoxic agents to targeted therapies that modulate
aberrant signaling networks. Current targeted anticancer
A recent study identified serum-derived exosomal drugs include agents directed at tyrosine kinases,
Cripto-1 as a novel, minimally invasive biomarker for angiogenesis, and CSCs. In this context, Cripto-1, owing
perihilar cholangiocarcinoma, with greater diagnostic to its aberrant expression across a broad spectrum of
sensitivity and specificity than conventional markers such malignancies, represents a promising therapeutic target.
as CA19-9 and cancer embryonic antigen (CEA). While However, while the therapeutic rationale is strong, the
61
these results are promising, they are based on a single research landscape presents both opportunities and
exploratory study and require validation in larger, multi- challenges.
center cohorts before clinical implementation. In renal Key modalities in targeted drug development include
cell carcinoma (RCC), both in vitro and in vivo studies monoclonal antibodies, peptides, and small-molecule
have demonstrated that Cripto-1 overexpression induces inhibitors. Among these, antibody-based therapies have
EMT, enhancing tumor metastasis. Notably, combining shown particular promise due to their high specificity
serum Cripto-1 levels with computed tomography (CT) and ability to engage immune-mediated mechanisms.
scan parameters improves diagnostic sensitivity for RCC Antibodies directed against Cripto-1 have been shown
compared to either method alone. However, the clinical to suppress the proliferation of melanoma, colon cancer,
62
utility of this integrative approach still remains to be and GBM cells. 64-66 However, these findings are primarily
confirmed through long-term prospective studies.
derived from in vitro studies and pre-clinical animal
In the realm of predictive modeling, Cripto-1 models, with limited clinical validation to date. Afify et
has shown potential utility in stratifying patients by al. optimized a bacteriophage expression system (T7) to
67
therapeutic responsiveness. Cripto-1 is highly expressed produce and purify human soluble Cripto-1 protein, which
in prostate CSCs, conferring resistance to radiotherapy exhibited a strong binding affinity for ALK-4 antibodies.
and chemotherapy. Tesar et al. evaluated the expression This interaction inhibited CSC self-renewal and promotion
63
of Cripto-1 along with p53, Bcl-2, nuclear factor-κB, of differentiation, underscoring the potential of Cripto-
and Ki67 in prostate cancer patients undergoing radical 1-based therapies in targeting tumor-initiating cells. To
radiotherapy, examining their associations with clinical further enhance specificity and reduce drug resistance,
parameters such as age, prostate-specific antigen, Gleason Annamaria et al. developed a humanized recombinant
68
score, tumor grade, and prognosis. Their proposed Fab antibody targeting Cripto-1, demonstrating effective
biomarker-based scoring system provides a theoretical binding in vitro and offering a foundation for next-

Volume 3 Issue 3 (2025) 88 doi: 10.36922/ARNM025130015